James W.M. Owens, Jr, MD, PhD

Adam Kelly, MD

Accredited by

American Academy of Neurology

Course Description


- Discuss the clinical efficacy—as measured by annualized relapse rate—of continuous ocrelizumab therapy versus two years of interferon followed by ocrelizumab therapy in this study of patients with relapsing multiple sclerosis (MS)

- State the proportion of patients who received continuous ocrelizumab therapy who were found to have no evidence of disease activity during the open label extension period of this study

- Describe various safety outcomes seen among patients with relapsing MS treated with continuous ocrelizumab therapy versus two years of interferon followed by ocrelizumab in this study

Activity Details

Credit Types:CME
Credit Amount:0.75 Credits
Release Date:2020-Sep-29
Expiration Date:2023-Sep-29
Registration Required:Yes
System Requirements:
CME programs are free for subscribers or can be purchased individually for $39.00.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.